A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia

NCT03771664 PHASE3 TERMINATED Results posted

This study is a randomized, double-blind, placebo-controlled study of the safety, tolerability, and efficacy of SAGE-217 compared to placebo in adult participants with comorbid major depressive disorder (MDD) and insomnia.

Details

Lead sponsor	Biogen
Phase	PHASE3
Status	TERMINATED
Enrolment	87
Start date	Mon Feb 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jan 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Major Depressive Disorder
• Insomnia

Interventions

• SAGE-217
• Placebo

Countries

United States